Brief: Sumitomo Pharma Oncology Presents Preliminary Data From Phase 1/2 Clinical Study Evaluating Investigational Agent Tp-3654 In Patients With Myelofibrosis
10/12/2022 23:59
Dec 10 (Reuters) - Sumitomo Pharma Co Ltd 4506.T :
* SUMITOMO PHARMA ONCOLOGY PRESENTS PRELIMINARY DATA FROM
PHASE
1/2 CLINICAL STUDY EVALUATING INVESTIGATIONAL AGENT TP-3654 IN
PATIENTS WITH MYELOFIBROSIS AT AMERICAN SOCIETY OF HEMATOLOGY
2022 ANNUAL MEETING & EXPOSITION
* SUMITOMO - PRELIMINARY FINDINGS FROM PHASE 1 DOSE
ESCALATION
STUDY INDICATED TP-3654 IS WELL TOLERATED WITH LIMITED
MYELOSUPPRESSIVE ADVERSE EVENTS
* OVERALL, TP-3654 APPEARS TO BE WELL TOLERATED WITH NO DOSE
LIMITING TOXICITY (DLT) TO DATE
Source text for Eikon: ID:nPn4GCghMa
Further company coverage: 4506.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sumitomo Pharma
See all newsSumitomo Pharma America Announces First Patient Receives Treatment In Phase 1/2A Study For Investigational Therapy Dsp-3077 For Retinitis Pigmentosa
Regarding A Report Concerning Sumitomo Pharma ( Company's Views On Gcr August 7 Report)
Brief: Sumitomo Pharma - Gotham City Research's August 3 Report Contains Numerous Statements That Are Clearly Inconsistent With Facts
Brief: Gotham City Research Holds Short Positions In Sumitomo Chemical And Sumitomo Pharmaceutical
Table: Sumitomo Pharma -Q1 group results (IFRS)